Request Demo
Atalanta loads crossbow with $97M, targeting neuro trial starts for 2 RNAi therapies
License out/inOligonucleotidesiRNA
Atalanta Therapeutics is loading its crossbow with $97 million from EQT Life Sciences, Sanofi Ventures, F-Prime Capital and Novartis Venture Fund, among others.
Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch Sanofi Ventures for its small interfeNovartis Venture Fundidates in epilepsy and Huntington’s disease.
Atalanta Therapeuticsries B financing was co-led by EQT Life Sciences and Sanofi Ventures, according to a Jan. 28 release. Existing investor F-Prime CapitaepilepsyoinedHuntington’s diseaseticipation from new investors Novartis Venture Fund, RiverVest Venture Partners, funds managed by abrdn, Pictet Alternative Advisors, the Mirae Asset Financial Group and the GHR Foundation.
The Boston biotech plans to submit investigational new drug (IND) applicatSanofi Venturesasking the FDA for approval to start in-human trials for two therapies. The candidates are divalent small interfering RNA (di-siRNovartis Venture Fundsilence certain genes in the central nervous system.Mirae Asset Financial GroupGHR Foundation
One asset, dubbed ATL-201, is designed to treat KCNT1-related epilepsy, an early-onset seizure disorFDA driven by variants in the KCNT1 gene. The protein coding gene is widely expressed in the brain, with KCNTI mutations tied to a range of epileptic disorders.
KCNT1-related epilepsy in infants and children cKCNT1-relatedre and frequent seizures tseizure disorderto be managed by available KCNT1seizure medications, according to Atalanta. The biotech’s siRNA candidate is designed to reduce KCNT1 levepileptic disorderseuronal excitability, according to the company.
KCNT1-relateddidate, ATL-101, is a di-siRNA targeting the HTT gene in patientseizuresuntington’s disease.seizureAtalantaKCNT1
“Importantly, this seATL-101will sudi-siRNApath to the cliHTT for two programs for sHuntington’s diseasediseases that today lack disease-modifying therapies—KCNT1-related epilepsy and Huntington’s disease—and will anchor our growing franchise of investigational medicines for Huntington’s disease,” Atalanta President and CEO Alicia Secor said in the release.
Atalanta emerged in 2021 with a $110 million series A and pacts with both Biogen and Genentneurological diseasesrship with Roche’s subsidiary remains intact, the Biogen deal is no longHuntington’s diseaseanta regaining full rights to two preclinical programs that were part ofHuntington’s diseasea sAtalantason told Fierce Biotech.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!